128 filings
Page 4 of 7
6-K/A
28eh aomhtoo
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
91s0 2qrqp4n
13 Jan 21
Current report (foreign)
4:00pm
6-K
jvj3zwyffcoo1h67 tlq
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K/A
8j28n83m10i9egqo8o
4 Jan 21
Current report (foreign) (amended)
6:36am
6-K
qvq2leoth8qgaypm9
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
ya6dy4mp5kc9clqdvtg8
10 Dec 20
Current report (foreign)
6:03am
6-K
id4i7
24 Nov 20
Current report (foreign)
6:03am
6-K
be0sdqluo14t xteg
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
i65nyw y62z7p6l
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
aulusyjbf9rk ofx3a6
5 Nov 20
Index to Unaudited Condensed Consolidated Financial Statements
6:02am
6-K
j3yad5 fh
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
rix mcom9mfp
14 Aug 20
Current report (foreign)
4:24pm
6-K
ss5venr9qezct y2s
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
13oylsmx 2121w36740u
7 Jul 20
Current report (foreign)
3:39pm
6-K
smx8n9
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
g6wig
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
w73baf5c gn96s78lq
9 Jun 20
Current report (foreign)
4:10pm
6-K
o913 dsfgm0it74
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
epfkb37b12p wuld
8 May 20
ObsEva Annual General Meeting 2020
4:38pm
6-K
7uheemqe gtisq4j
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am